Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy.

Anna S Lok,Mark S Sulkowski,Jens J Kort,Ira Willner,K Rajender Reddy,Mitchell L Shiffman,Mohamed A Hassan,Brian L Pearlman,Federico Hinestrosa,Ira M Jacobson,Giuseppe Morelli,Joy A Peter,Monika Vainorius,Larry C Michael,Michael W Fried,Gary P Wang,Wenjing Lu,Lois Larsen,David R Nelson

Gastroenterology（2019）

引用 33|浏览74

暂无评分

摘要

In a randomized study of patients with chronic HCV genotype 1 infection who received previous treatment with sofosbuvir plus an NS5A inhibitor, 16 weeks treatment with G/P produced an SVR12 in more than 90% of patients, including those with compensated cirrhosis. ClinicalTrials.gov no: NCT03092375.

查看译文

关键词

Drug Resistance Variant,DAA Experienced,Protease Inhibitor,Compensated Cirrhosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要